BOEHRINGER-INGELHEIM
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.1 In September, the U.S. Food and Drug Administration (FDA) approved nintedanib as the first and only medicine to slow the rate of decline in pulmonary function in adults living with SSc-ILD. Regulatory approvals for the treatment of patients living with SSc-ILD have also been granted in other countries including Canada, Japan and Brazil.
Systemic sclerosis (SSc), also known as scleroderma, is a disfiguring, disabling and potentially fatal rare autoimmune disease.3,4,5 It causes scarring (fibrosis) of various organs, including the lungs, heart, digestive tract and kidneys and can have life-threatening complications. When SSc affects the lungs, it can cause interstitial lung disease (ILD), known as SSc-ILD.2,6 ILD is the leading cause of mortality in SSc, accounting for almost 35% of SSc-related deaths.7
“SSc-ILD is a life-changing disease. Once fibrosis of the lungs occurs it cannot be reversed, and this can have a devastating impact on a patient’s life and daily activities” said Peter Fang, Senior Vice President and Head of Therapeutic Area Inflammation at Boehringer Ingelheim. “Striving to improve the lives of people living with pulmonary fibrosis, we are pleased with the Committee’s positive opinion, which represents an important step forward in helping to slow down the progression of this rare and life-changing disease.”
The positive opinion was based on the results of the SENSCIS® trial, a phase III, double-blind, placebo-controlled trial conducted to investigate the efficacy and safety of nintedanib in patients with ILD-associated systemic sclerosis (SSc-ILD).2 The primary endpoint was the annual rate of decline in Forced Vital Capacity (FVC) assessed over a 52-week period. Patients remained on the study treatment for at least 52 weeks of treatment or for a maximum of 100 weeks of treatment. Results showed nintedanib slowed the loss of pulmonary function by 44% (41mL/year) relative to placebo, as measured in FVC over 52 weeks.2 The adverse-event profile of nintedanib was similar to that observed in patients with idiopathic pulmonary fibrosis, with the most common adverse event being diarrhoea.2
~ENDS~
Please click on the link for ‘Notes to Editors’ and ‘References’: https://www.boehringer-ingelheim.com/press-release/chmpopinionnintedanibssc-ild
View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005212/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FLATEXDEGIRO-AG25.4.2024 20:20:33 CEST | Press release
flatexDEGIRO Starts Into Expected Record Year 2024 With a Jump in Revenues and Earnings
CA-OPENGATE-CAPITAL25.4.2024 19:15:32 CEST | Press release
OpenGate Capital Completes Sale of SMAC
FARCANA25.4.2024 17:41:30 CEST | Press release
Farcana Announces Gateway: Showdown - Playtest Kicks Off April 30th, with a 1,000,000 $FAR token prize pool!
ANTOGNOLLA25.4.2024 16:40:29 CEST | Press release
Antognolla at International Hospitality Investment Forum: Growing Interest in the Italian Market from Hotel Operators and Investors
CA-LASERFICHE25.4.2024 16:31:29 CEST | Press release
Digital Transformation’s Next Era: Generative AI and Laserfiche 12 at 2024 Empower Conference
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom